Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy

Life Sci. 1999;65(24):2573-80. doi: 10.1016/s0024-3205(99)00526-3.

Abstract

Vascular endothelial growth factor (VEGF), the strongest known angiogenic cytokine and also a potent enhancer of vascular permeability, is closely associated with diabetic ocular complications and other intraocular neovascular diseases. The therapeutic effect of VEGF-neutralizing antibody on oxygen-induced retinopathy in an experimental murine model of proliferative retinopathy was investigated. Intraocular and systemic injection of the antibody resulted in 46% and 18% reductions in the number of nuclei of newly formed vessels of this model, respectively. The results demonstrated that a neutralizing antibody against VEGF was highly effective in the treatment of intraocular neovascularization and suggested possible modes of therapy in human intraocular neovascular diseases, including diabetic proliferative retinopathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Antibodies / immunology
  • Antibodies / pharmacology*
  • Diabetic Retinopathy / therapy
  • Disease Models, Animal
  • Endothelial Growth Factors / antagonists & inhibitors*
  • Endothelial Growth Factors / immunology*
  • Female
  • Humans
  • Infant, Newborn
  • Injections, Subcutaneous
  • Lymphokines / antagonists & inhibitors*
  • Lymphokines / immunology*
  • Mice
  • Mice, Inbred C57BL
  • Oxygen / toxicity
  • Pregnancy
  • Rabbits
  • Retinal Neovascularization / therapy
  • Retinopathy of Prematurity / therapy*
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Substances

  • Antibodies
  • Endothelial Growth Factors
  • Lymphokines
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Oxygen